Albireo gets FDA, European approval for pediatric liver disease drug

Albireo Pharma, a rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for a drug for a pediatric liver disease called progressive familial intrahepatic cholestasis (PFIC).